Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials)

There are currently no approved pharmacological treatments to improve social reciprocity and limit repetitive and rigid behaviors in autism spectrum disorder (ASD). We describe the design of two Phase III studies evaluating the efficacy/safety of bumetanide oral liquid formulation in ASD. These are...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Autism Dev Disord
Autors principals: Crutel, Véronique, Lambert, Estelle, Penelaud, Pierre-François, Albarrán Severo, Cristina, Fuentes, Joaquin, Rosier, Antoine, Hervás, Amaia, Marret, Stéphane, Oliveira, Guiomar, Parellada, Mara, Kyaga, Simon, Gouttefangeas, Sylvie, Bertrand, Marianne, Ravel, Denis, Falissard, Bruno
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2020
Matèries:
Original Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8254707/
https://ncbi.nlm.nih.gov/pubmed/33151500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10803-020-04709-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars